Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02802241 · ClinicalTrials.gov registry record · NA
Effects of Open-label vs Double-blind Treatment in IBS
A NA study of Irritable Bowel Syndrome and Placebo Effect, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 340
- Enrollment target
- 1
- Study location
NCT02802241: Completed NA study of Irritable Bowel Syndrome and Placebo Effect, sponsored by Beth Israel Deaconess Medical Center.
NCT02802241 is a NA study of Irritable Bowel Syndrome and Placebo Effect that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 340 participants, above the 137-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (148% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02802241, a NA study of Irritable Bowel Syndrome and Placebo Effect, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
Primary Outcome
Score ranges from 0-500, 0 indicates no symptoms, 500 indicates worst possible symptoms
Conditions Studied
Interventions
- DRUG placebo
- DIETARY_SUPPLEMENT peppermint oil
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2016-06 |
| Est. Completion | 2019-01 |
| Phase | NA |
What the finished NCT02802241 record still lists
NCT02802241 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, above the 137-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (148% higher).
The record links to 4 conditions, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02802241 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02802241 about?
NCT02802241 is a clinical study titled "Effects of Open-label vs Double-blind Treatment in IBS". The purpose of this study is to investigate placebo effects and peppermint oil in Irritable Bowel Syndrome.
What is the current status of trial NCT02802241?
This trial is currently completed. It is a NA study. The enrollment target is 340 participants. The study started on 2016-06. Estimated completion is 2019-01.
What conditions does trial NCT02802241 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome, Placebo Effect, Placebos, Peppermint Oil.
What interventions are being tested in trial NCT02802241?
The interventions under investigation include: placebo (DRUG), peppermint oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02802241?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02802241 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02802241's enrollment target sits among peer trials
340 6th of 47 higher than 42 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
-
IBS Skin Patch Test Food Allergy Study
RECRUITING · NA
-
Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome
RECRUITING · NA
-
Well-being in IBS: Strengths and Happiness (WISH) 2.0
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia